Cargando…

Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells

BACKGROUND: CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and reinfusion of CAR-T cells is not always effective. Sequential infusion of humanized CD19-modified and CD22-modified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Fei, Zhang, Jian, Zhang, Xinyou, Tian, Mengli, Wang, Jingjing, Kang, Liqing, Qiu, Huiying, Wu, Depei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438143/ https://www.ncbi.nlm.nih.gov/pubmed/30988623 http://dx.doi.org/10.2147/OTT.S189103

Ejemplares similares

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
por: Yan, Lingzhi, et al.
Publicado: (2020)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021)

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
por: Liu, Sining, et al.
Publicado: (2023)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: LI, Tingting, et al.
Publicado: (2023)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL
por: Zheng, Peihao, et al.
Publicado: (2023)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
por: Gu, Runxia, et al.
Publicado: (2020)

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
por: Wullenkord, Ramona, et al.
Publicado: (2020)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report
por: Htun, Kyaw Thu, et al.
Publicado: (2021)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
por: Zhang, Yu, et al.
Publicado: (2022)

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
por: Zhang, Li-Na, et al.
Publicado: (2018)

Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity
por: Zhang, Na, et al.
Publicado: (2022)

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient
por: Zou, Rui, et al.
Publicado: (2023)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells
por: Grain, Audrey, et al.
Publicado: (2023)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy
por: Yang, Chunmei, et al.
Publicado: (2020)

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
por: Dai, Hai-ping, et al.
Publicado: (2022)

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
por: Ma, Yunju, et al.
Publicado: (2023)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
por: Zhang, Ying, et al.
Publicado: (2021)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023)

Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
por: Wang, Jia, et al.
Publicado: (2020)

P1380: THE COMPOSITION OF INFUSED CD19-CAR-T PRODUCT IMPACTS ON EFFICACY
por: Bellesi, Silvia, et al.
Publicado: (2023)

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021)

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
por: Cordoba, Shaun, et al.
Publicado: (2021)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
por: Xu, Xinjie, et al.
Publicado: (2019)

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
por: Cao, Xuanqi, et al.
Publicado: (2022)

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7uq2udu41hhctkg5b9vohrlt85